Intravitreal faricimab improves outcome in treatment-resistant patients with nAMD

Patients with neovascular age-related macular degeneration (nAMD) resistant to treatment with intravitreal aflibercept (IVA) may benefit from intravitreal faricimab (IVF), according to a study.

In this retrospective review, data from 55 patients with nAMD who underwent ≥6 IVA treatments during the previous 12 months or ≥4 IVA treatments during the previous 6 months were analyzed. All patients had a central macular thickness (CMT) on optical coherence tomography (OCT) of ≥300 microns, and had observable intraretinal and/or subretinal fluid on OCT.

There were 28 patients who switched from IVA to IVF who received 3 treatments within 4 months and 27 patients who remained on IVA and received 3 treatments within 4 months.

At the end of the 4-month study period, 39.3% of patients who switched to IVF and 7.4% of patients who remained on IVA had a CMT of <300 microns without retinal fluid on OCT, and 35.7% and 7.4%, respectively, gained ≥2 lines of visual acuity.

The authors cautioned that studies with longer follow-up periods are needed to determine if the outcomes can be maintained.

Reference
Rush RB, Rush SW. Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Clin Ophthalmol. 2022;16:4041-4046. doi: 10.2147/OPTH.S395279. PMID: 36532820; PMCID: PMC9747838.